Mark Leonard Singleton, the SVP & CFO of $BVS, sold 5,479 shares of the company on 03-24-2025 for an estimated $53,639. We received data on the trade from a recent ...

The price trend for Bioventus (BVS) has been bearish lately and the stock has lost 6.4% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that ...

Bioventus (NASDAQ:BVS) gains attention as orthobiologic innovation aligns with Nasdaq Today healthcare sentiment.

Bioventus develops musculoskeletal therapies including biologics and nerve stimulation systems. Discover company developments ...

On Tuesday, Bioventus Inc. (NASDAQ:BVS) reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents. The medical device company reported sales of $153.6 million ...

Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment ...

Bioventus (NASDAQ:BVS) just reported results for the first quarter of 2024. Bioventus reported earnings per share of 7 cents. This was above the analyst estimate for EPS of -7 cents. The company ...